MIPS Accelerator Certification
The MIPS Accelerator 6 Modular EHR, SLI Compliance Certificate #15.02.05.1598.HEAL.01.03.0.220117 (cert. date January 17, 2022), meets ONC 2015 certified EHR requirements for ambulatory settings for all EP electronic reporting measures. Access to data requires paying for the optional QM Accelerator service as specified in a Service Agreement.
This Health IT Module is 2015 Edition compliant and has been certified by an ONC-ACB in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services. View our certification here. This certification does not represent an endorsement by the U.S. Department of Health and Human Services. ONC Certified HIT® is a registered trademark of HHS.
Supported Measures
As an ONC Certified HIT, we are certified to report on 70 electronic clinical quality measures. Our application calculates the best quality score for each clinician, thereby putting your best foot forward and qualifying you for the highest Merit-based Incentive Payment System score possible.
The 70 quality measures are:
CMS2v11: Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan
CMS22v10: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
CMS50v10: Closing the referral loop: receipt of specialist report
CMS52v4: HIV/AIDS: Pneumocystis jiroveci pneumonia (PCP) prophylaxis
CMS56v10: Functional Status Assessment for Hip Replacement
CMS61v5: Preventive Care and Screening: Cholesterol – Fasting Low Density Lipoprotein (LDL-C) Test Performed
CMS62v4: HIV/AIDS: Medical Visit
CMS64v5: Preventive Care and Screening: Risk-Stratified Cholesterol – Fasting Low Density Lipoprotein (LDL-C)
CMS65v5: Hypertension: Improvement in Blood Pressure
CMS66v10: Functional Status Assessment for Knee Replacement
CMS68v11: Documentation of Current Medications in the Medical Record
CMS69v10: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
CMS74v11: Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists
CMS75v10: Children Who Have Dental Decay or Cavities
CMS77v4: HIV/AIDS: RNA Control for Patients with HIV
CMS82v3: Maternal Depression Screening
CMS90v11: Functional Status Assessment for Complex Chronic Conditions
CMS117v10: Childhood Immunization Status
CMS122v10: Diabetes: Hemoglobin A1c Poor Control
CMS123v4: Diabetes: Foot Exam
CMS124v10: Cervical Cancer Screening
CMS125v10: Breast Cancer Screening
CMS126v4: Use of Appropriate Medications for Asthma
CMS127v10: Pneumonia Vaccination Status for Older Adults
CMS128v10: Anti-depressant Medication Management
CMS129v11: Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
CMS130v10: Colorectal Cancer Screening
CMS131v10: Diabetes: Eye Exam
CMS132v4: Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures
CMS133v10: Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
CMS134v10: Diabetes: Medical Attention for Nephropathy
CMS135v10: Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
CMS136v11: ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication
CMS137v10: Initiation and Engagement of Alcohol and Other Drug Dependence Treatment
CMS138v10: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
CMS139v10: Falls: Screening for Future Fall Risk
CMS140v4: Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
CMS141v5: Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients
CMS142v10: Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
CMS143v10: Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation
CMS144v10: Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
CMS145v10: Coronary Artery Disease (CAD): Beta-Blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)
CMS146v10: Appropriate Testing for Children with Pharyngitis
CMS147v11: Preventive Care and Screening: Influenza Immunization
CMS148v4: Hemoglobin A1c Test for Pediatric Patients
CMS149v10: Dementia: Cognitive Assessment
CMS153v10: Chlamydia Screening for Women
CMS154v10: Appropriate Treatment for Children with Upper Respiratory Infection (URI)
CMS155v10: Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents
CMS156v10: Use of High-Risk Medications in the Elderly
CMS157v10: Oncology: Medical and Radiation – Pain Intensity Quantified
CMS158v4: Pregnant women that had HBsAg testing
CMS159v10: Depression Remission at Twelve Months
CMS160v4: Depression Utilization of the PHQ-9 Tool
CMS161v10: Adult Major Depressive Disorder (MDD): Suicide Risk Assessment
CMS163v4: Diabetes: Low Density Lipoprotein (LDL) Management
CMS164v4: Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
CMS165v10: Controlling High Blood Pressure
CMS166v5: Use of Imaging Studies for Low Back Pain
CMS167v4: Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
CMS169v4: Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use
CMS177v10: Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment
CMS179v4: ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range
CMS182v5: Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
CMS249v4: Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture
CMS347v5: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease
CMS349v4: HIV Screening
CMS645v5: Bone density evaluation for patients with prostate cancer and receiving androgen deprivation therapy
CMS646v2: Intravesical Bacillus-Calmette-Guerin for non-muscle invasive bladder cancer
CMS771v3: International Prostate Symptom Score (IPSS) or American Urological Association-Symptom Index (AUA-SI) Change 6-12 Months After Diagnosis of Benign Prostatic Hyperplasia